Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL):  Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided 1L Consolidation Therapy Strong Execution and Increased Investigator Interest Accelerated 2026 Site